A Real-Time PCR Assay for Rapid Identification of Inducible and Acquired Clarithromycin Resistance in Mycobacterium abscessus

Meenu Kaushal Sharma (✉ meenu.sharma@canada.ca)
Public Health Agency of Canada  https://orcid.org/0000-0002-6020-9995

Yanni La
University of manitoba

Debra Janella
Public Health Agency of Canada

Hafid Soualhine
Public Health Agency of Canada

Research article

Keywords: Mycobacterium abscessus, real-time PCR, erm(41), clarithromycin

DOI: https://doi.org/10.21203/rs.3.rs-38897/v4

License: ☒ ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** *Mycobacterium abscessus* is a rapidly growing mycobacteria involved in severe infections of the lung, skin, or soft tissue. Macrolides such as clarithromycin are the recommended first line drugs for treatment of *M. abscessus* infections. However, *M. abscessus* has dual mechanisms of resistance to macrolides, making treatment by macrolides difficult. A functional *erm*(41) gene confers for inducible resistance while acquired mutations on the 23S rRNA *rrl* gene confer for constitutive resistance.

**Methods:** We have developed a real-time PCR assay to detect both inducible and acquired resistance to clarithromycin, and compared the results to traditional *erm*(41) and *rrl* sequencing and phenotypic susceptibility testing using Sensititre™ plates.

**Results:** Of the total 126 *M. abscessus* isolates tested, truncated *erm*(41) was found in 23/126 (18.3%) of the samples, 27/126 (21.4%) had a T28C mutation in *erm*(41), and 2/126 (1.6%) had an acquired A2058C mutation in *rrl*. The phenotypic results correlated with the expected sequencing results in 121/126 samples (96%). Phenotypic testing compared to real-time PCR resolved 2 of these discrepancies by showing the existence of both *erm*(41) alleles in the isolates that sequencing missed. One culture was found to be mixed with two *M. abscessus* subsp. as per *hsp65* sequencing and 2 isolates had discordance between molecular and phenotypic results. It was presumed that 3 isolates showed discrepancy between sequencing and real-time PCR, but one culture was mixed and other 2 detected both alleles by real-time PCR leading to 100% concordance when compared to sequencing.

**Conclusion:** In conclusion, real-time PCR is more accurate for detection of both acquired and induced clarithromycin resistance, specifically when mixed genic profiles are present in a sample.

**Background**

As per former and accepted taxonomy, the rapidly growing *Mycobacterium abscessus* is subdivided to 3 subspecies *M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *bolletii*, and *M. abscessus* subsp. *massiliense* which are involved in infections of the skin, lung, as well as infections associated with medical procedures [1,2]. These infections are commonly treated with macrolides (clarithromycin, azithromycin and erythromycin) but resistance to macrolides makes treatment increasingly difficult [3,4]. *M. abscessus* infections management may require multi-drug therapy along with intravenous treatment for several months. Intravenous agents such as amikacin are commonly associated with side effects in patients [5]. Identifying resistance earlier can determine the best suited treatment. According to the Clinical Laboratory Standard Institute (CLSI), drug susceptibility testing for clarithromycin require an incubation time of up to 14 days to assess inducible resistance [6].

Natural and acquired resistance to clarithromycin are due to the erythromycin ribosomal methyl transferase, *erm*(41), and the gene encoding a 23S peptidyl transferase in the large 23S ribosomal subunit, *rrl*, respectively [7,8,9]. Inducible resistance occurs naturally with a functional *erm*(41) gene [7]. However, a common trait of *M.
abscessus subsp. massiliense isolates is that they have a 274-bp deletion in \(erm(41)\), making it non-functional, hence susceptible to macrolides [7]. Thus, \(M. \text{abscessus}\) subspecies identification and determination of macrolide susceptibility are useful in the planning of the appropriate treatment. Another mutation, the T to C mutation at position 28 on \(erm(41)\) also leads to a non-functional erythromycin ribosomal methyl transferase [7]. When inducible resistance occurs, drug susceptibility testing will show susceptibility \textit{in vitro} at day 3 but will later develop resistance up to 14 days post-incubation. Clinically acquired resistance to a macrolide occurs from a spontaneous mutation at positions 2058 and 2059 on the \(rrl\) gene of 23S, which causes an alteration to the drug binding pocket of the protein [8, 9]. Constitutive resistance will result in a high minimum inhibitory concentration (MIC) at day 3 of susceptibility testing. As reported by Vester et al (2001), acquired mutations at positions 2057 and 2611 on \(rrl\) can also result in low level resistance due to being in close proximity to the action centre [10]. These mutations are outside the focal point of macrolide interaction but can still disrupt the structure of the drug binding pocket, reducing its ability to inhibit the ribosome [10].

Sequencing of 16S and \(hsp65\) (heat shock protein 65) genes was also used to identify the different subspecies of \(M. \text{abscessus}\). Sequencing of \(erm(41)\) and \(rrl\) was done and probes for real-time PCR were designed to look for possible mutations that would cause resistance to clarithromycin. A real-time PCR assay was designed to run under a single condition which would greatly decrease the turnaround time of 14 days using phenotypic testing, to just a few hours to predict resistance to clarithromycin. Real-time PCR assay was also compared to the sequencing method currently used in our laboratory.

**Methods**

**Identification of \(M. \text{abscessus}\) subspecies**

\(M. \text{abscessus}\) isolates identification was performed using 16S gene sequencing and the subsp. identification was done using sequencing of the \(hsp65\) gene. PCR amplification was done in a 50 \(\mu\)L reaction volume consisting of 47.5 \(\mu\)L premix (1 \(\mu\)M forward primer, 1 \(\mu\)M reverse primer), 0.25 \(\mu\)L of Qiagen Taq DNA polymerase (Qiagen, Hilden, Germany), and 2.5 \(\mu\)L of template DNA (Table 1). Amplification was done using the Applied Biosystems Veriti® 96-Well Thermal Cycler (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY). Thermocycler conditions for \(hsp65\) were 95°C for 5 min, 45 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min, followed by 72°C for 5 min. The PCR products were purified using PCRClean DX magnetic beads (Aline Biosciences, Woburn, MA). Sequencing was done using Applied Biosystems 3730xl DNA Analyzer (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY). Sequences were assembled using Lasergene SeqMan Pro (DNASTar, Inc., Madison, WI) and sequence comparison was done using BioNumerics 7.6.2 software. Reference strains \(Mycobacterium \text{abscessus}\) subsp. \(abscessus\) ATCC 19977\(^T\), \(Mycobacterium \text{abscessus}\) subsp. \(bolletii\) CCUG 50184\(^T\), and \(Mycobacterium \text{abscessus}\) subsp. \(massiliense\) CCUG 48898\(^T\) were used.

**Antimicrobial susceptibility testing**

Phenotypic susceptibility testing for clarithromycin was done using Sensititre™ RAPMYCO AST plates (Trek Diagnostics, Thermo Fisher Scientific, Oakwood Village, OH) according to the manufacturer instructions. Plates were examined for the drug MICs on day 3 (and day 5 if growth in positive control well was not adequate) of
incubation then further incubation at 30°C was done if day 3 or 5 results showed sensitivity. Plates were examined for inducible resistance on day 7, 10 and 14 of incubation.

**Sequencing of erm(41) and rrl genes**

PCR amplification was done in a total reaction volume of 50 μL which consisted of 25 μL Amplitaq Gold® 360 Mastermix (Thermo Fisher Scientific, Applied Biosystems, Foster City, CA), 22.5 μL forward and reverse primers (final concentration of 1 μM each), and 2.5 μL of template DNA for both erm(41) and rrl genes. Primers ermF and ermR1 were used to amplify the erm(41) gene while primers 19F and 21R amplified the rrl gene (Table 1). Thermocycler conditions for amplifying erm(41) were 95°C for 7.5 min for the initial denaturation, followed by 35 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec followed by a final extension of 72°C for 10 min. Conditions were the same for rrl except with an annealing temperature of 55°C instead of 60°C. The PCR products were purified using PCRClean DX magnetic beads. Sequencing primers are shown in Table 1. Sequencing and analysis were done as described above for *hsp65* gene.

**Real-time PCR assay**

A 96-well plate assay was designed based on a modified protocol from Shamira Shallom and colleagues (2015) [11]. The probe, Absc-chel 16S, was used for identification, erm(41)_probe1 was used to detect full-length erm(41), SNPs on position 28 of erm(41) were detected using probes erm(41)T28 and erm(41)C28, SNPs on position 2058 of rrl were detected using probes 23S_A2058 and 23S_C2058 (Table 2). Probes for rrl, 23S_A2058 and 23S_C2058, initially consisted of LNA (locked nucleic acids) from the Shallom protocol, however, the rrl probes used in this experiment were modified. This change would see a lower melting temperature for these probes and therefore, the 5’ end of these probes were extended by 7 base pairs using Mabs5 23S rRNA (GenBank accession number EU980535.1) to ensure the same melting temperature of around 60°C. Probes were made to a working concentration of 2.5 μM in a mix with their corresponding primers (Table 2) which were diluted to 10 μM. Reactions were done in a total reaction volume of 25 μL consisting of 12.5 μL TaqMan® Fast Advanced Master Mix (Thermo Fisher Scientific, Life Technologies, Austin, TX.), probes final concentration of 250 nM and forward and reverse primers at final concentration of 1 μM each, and 3.75 μL of template DNA. Each sample was run in duplicates with positive control for all wild type and mutants i.e., 16S, full length erm(41), T28T in erm(41), T28C in erm(41), A2058A in rrl, and A2058C in rrl and negative control (no sample DNA). Real-time PCR was done using the Applied Biosystems QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY). Thermocycler conditions included an initial denaturation of 95°C for 3 min, 40 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.

**Results**

The *hsp65* sequences were compared using Bionumerics version 7.6.2 (Applied Math, Belgium). Sequential differences in *hsp65* were used to distinguish the three members of *M. abscessus* as described in Kazue Nakanaga et al (2014) [18]. It was found that in our 126 samples, 94 were identified as *M. abscessus* subsp. abscessus, 7 *M. abscessus* subsp. bolletii, 23 *M. abscessus* subsp. massiliense, and 2 showed the coexistence of two mixed DNA populations belonging to *M. abscessus* subspecies.
Clarithromycin susceptibility testing using microbroth dilution assay found that of the 126 isolates, 3 were resistant on day 3 (2 *M. abscessus* subsp. *abscessus*, 1 *M. abscessus* subsp. *massiliense*), 76 were inducibly resistant (70 *M. abscessus* subsp. *abscessus*, 5 *M. abscessus* subsp. *bolletii*, 1 *M. abscessus* subsp. *massiliense*). One isolate with intermediate result (*M. abscessus* subsp. *abscessus*) was repeated with an updated phenotypic result showing susceptible result giving a total of 47 susceptible results (22 *M. abscessus* subsp. *abscessus*, 2 *M. abscessus* subsp. *bolletii*, 21 *M. abscessus* subsp. *massiliense*, 2 mixed by hsp65 sequencing) (Table 3). Inducible resistance is characterized by an MIC of 8 or greater observed on day 7 and up to day 14 after an initial result of susceptibility at day 3 [19].

**Sequencing of *erm(41)* and *rrl* for mutations**

Sequencing found that 23 samples had the 274-bp deletion on *erm(41)*. Twenty-two of which were found to be in the subspecies *M. abscessus* subsp. *massiliense*. One was in a mixed population containing *Mycobacterium abscessus* subsp. *massiliense* (Table 4). Twenty-seven strains had the T28C mutation in *erm(41)* (24 *M. abscessus* subsp. *abscessus*, 2 *M. abscessus* subsp. *bolletii*, and 1 mixed) and 2 strains harboured a A2058C mutations on *rrl* (1 *M. abscessus* subsp. *abscessus* and 1 *M. abscessus* subsp. *massiliense*) (Table 4). Five strains (*M. abscessus* subsp. *abscessus*) had discrepant results which had phenotypic results that did not match with the mutation found with sequencing, which have been explained in the discussion section.

**Real-time PCR Assay**

Our real-time assay was optimized by modifying Shallom 2015 protocol. Our method ran all of the targeted mutations of a sample on a single plate and under the same PCR conditions which include detection of full-length *erm(41)*. Shallom et al used a SYBR green quantitative method separate from their probe based one for detecting full-length *erm(41)*. Additionally, we used a probe for species confirmation in our assay, making our assay far more informative in a single run. The probes for the *rrl* targets originally consisted of LNA bases, but due to availability, ours consist of regular DNA bases. The probes' length was then changed from 12 to 19 base pairs to ensure a matching melting temperature with other reactions on the plate. This has impact on the real-time PCR conditions as we intend to multiplex this assay at a later date. Black Hole quencher probe tags were also used in place of Iowa Black fluorescent tags for the modified *rrl* probes. These modified probes were locally produced in our facility and therefore more cost effective and allowed the assessment of different probe and conditions. Results of the real-time assay showed amplification for all our targets using the aforementioned probes under the same cycling conditions. Successful detection in our *rrl* targets informs us that LNA bases in probes is not necessary to perform this assay. Crossing threshold (CT) values were found to range between 16 and 24 cycles for different reactions (Figure 1). Samples were run in duplicates and CT values of duplicates showed minimal variability of one CT with orange color having slightly more variability between duplicates.

When real-time PCR assay was compared to sequencing, one discrepant sample had a truncated *erm(41)* gene with the T allele with sequencing, but real-time PCR showed detection of a full-length gene and a C allele. Both methods found no mutations on position 2058 of the *rrl* gene. This strain was found to be mixed with *M. abscessus* subsp. *abscessus* and *M. abscessus* subsp. *massiliense* as per hsp65 sequencing data. Two isolates of *M. abscessus* subsp. *abscessus* had discordant sequencing and phenotypic results, with both T and C alleles of *erm(41)* amplified with real-time PCR and only T28C mutation with sequencing. Hence, only
sequencing showed discrepancy to the phenotypic results but real-time PCR did not as the latter detected both alleles. Real-time PCR results resolved all these three discrepancies.

Discussion

Clarithromycin is an important antibiotic against members of the *M. abscessus* [3]. Resistance to macrolide can be predominantly correlated with two genes, *erm*(41) and *rrl* in *M. abscessus*. The full *erm*(41) gene that is without the 274 bp deletion and T at position 28 will result in a functional erythromycin ribosomal methyl transferase and hence show inducible resistance [7]. Extended periods of incubation in the antibiotic will induce resistance in *M. abscessus* isolates that have an inducible resistance genic profile. An acquired point mutation on positions 2058 and/or 2059 of *rrl* will result in high level resistance against clarithromycin by altering the drug binding domain of the 23S rRNA [8, 9]. These are characteristically shown by resistance (MIC ≥ 8) on day 3 of antimicrobial susceptibility testing and hence indicate constitutive resistance.

Phenotypic susceptibility testing was done by broth microdilution and samples were incubated for up to 14 days [6]. Initial testing found that 79 (62.7%) samples were resistant of which 76 (60.3%) showed inducible resistance. Forty-six were initially shown to be susceptible at day 3; however, one sample with an initial intermediate result was repeated and showed to be sensitive for a total of 47 (37.3%) sensitive samples. For this intermediate sample, molecular methods found it to have a T28C mutation so a susceptible result was expected and overgrowth in the initial phenotypic testing may be the cause for the intermediate reading. In the 2 strains that were determined to be mixed by *hsp65* sequencing, both were susceptible to clarithromycin.

Sequencing of *erm*(41) and *rrl* identified 27 strains (21.4%) with a T28C mutation, 23 (18.3%) had a truncated *erm*(41) gene and 2 (1.6%) with the A2058C mutation on *rrl*. The 274-bp deletion on *erm*(41) was identified in only *M. abscessus* subsp. *massiliense* and 1 mixed *M. abscessus* sample containing *M. abscessus* subsp. *massiliense*. This deletion is characteristic of *M. abscessus* subsp. *massiliense* as reported by Hee-youn Kim et al (2010) which is why clarithromycin treatment is found to be more effective against infections with *M. abscessus* subsp. *massiliense* than the other subspecies that contain the functional full-length gene [20]. One sample in our study that was identified as *M. abscessus* subsp. *massiliense* was found to possess a full-length *erm*(41) gene by both sequencing and real-time PCR. Shamira Shallom and colleagues (2013) have also identified *M. abscessus* subsp. *massiliense* isolates with full-length *erm*(41) in which they suggest is probably due to horizontal transfer [21].

Sequencing results of *erm*(41) and *rrl* were 96.0% (121/126) concordant with the phenotypic results, with 5 isolates of *M. abscessus* found to have phenotypic results discordant with the molecular results. Two isolates of *M. abscessus* subsp. *abscessus* showed inducible resistance phenotypically, but had the T28C mutation found with sequencing for an expected result to clarithromycin susceptibility. For these two isolates, both T and C alleles on position 28 of *erm*(41) were detected in the real-time PCR assay, showing that both alleles were present and that the real-time PCR method uses a probe based detection and hence was more sensitive than sequencing. Our sequencing method only detected the predominant C allele for this sample as in general, a sequencing method will more frequently utilize DNA template containing a predominant allele. However, real-time PCR can detect both most and less predominant alleles in low DNA concentrations. Another isolate showed an inducible resistant result phenotypically without a corresponding allele. This could not be resolved
when both phenotypic and molecular assays were repeated and is likely due to another mutation outside the gene fragments used in this study. Efflux pump ability has been shown to be directly involved with clarithromycin resistance [22]. One isolate that showed a phenotypic susceptible result lacked correlation with genotypic mutations and also could not be resolved when repeated testing showed reproducibility on all assays. This is perhaps due to unknown mechanism that renders the isolate susceptible to clarithromycin. Extending the search to look for additional mutations did not show $erm(41)$ C19T and hence evidence of susceptibility is lacking [23]. The fifth discordant result was resistant on day 3 of susceptibility testing indicating an acquired resistance to clarithromycin, but had no mutations found on positions 2058 of $rrl$ with sequencing. This is suspected to be caused by a point mutation elsewhere on $rrl$ that would affect the drug binding pocket. The discrepant strains that could be resolved by $hsp65$ or real-time PCR had their clarithromycin phenotypic susceptibility testing repeated with 3 of the final results staying reproducible to the initial results. There were no additional mutations in the $rrl$ gene such as A2056G, A2057G, A2080C, G2068A, A2269G, G2281A, as the sequence matched wild type [10,23].

A real-time assay was developed to assess resistance in $M. abscessus$ isolates by targeting mutations that were found in sequencing. The assay was built upon the protocol in Shallom et al (2015) for $erm(41)$ and $rrl$ with primer and tag modifications that allowed us to perform amplification under a single cycling condition; and included additional probes for 16S identification and full length $erm(41)$ detection [12,16,17]. A probe for detecting the 16S gene of $M. abscessus$ was used to confirm that samples were members of the $M. abscessus$ and verified that $erm(41)$ is present [16]. Discrimination of full-length and truncated $erm(41)$ was done by having a probe and the reverse primer hybridize the region of the gene that is deleted. Amplification indicates a full-length $erm(41)$ gene [17]. Two sets of probes were used to detect the mutant and wild type alleles for each position 28 of $erm(41)$ and position 2058 of $rrl$ [12]. With all of the included probes in our assay, identification and mutation detection can be determined for a sample after a single real-time PCR run. Compared to the 3-14 days needed for susceptibility testing, this modified real-time PCR method has significant impact in a clinical laboratory as it is much faster and helps in determining the best treatment. Samples were run in duplicates and were found to have similar CT and $\Delta$Rn values (Figure 1) for each target, showing the high reproducibility of the assay and had CT values ranging from 16 to 24 for all reactions. Real-time results were compared to the sequencing data to examine adequate amplification in our assay. The real-time results confirmed the sequencing results in our samples. One sample showed a truncated $erm(41)$ gene in sequencing, but detection of the full-length gene was observed with real-time PCR. Upon repeating $hsp65$ sequencing for this discrepancy, it was found to be mixed with both $M. abscessus$ subsp. abscessus and $M. abscessus$ subsp. massiliense. Hence, both test results were correct. Two samples detected both alleles of $erm(41)$ by real-time PCR whereas sequencing only detected single C allele. The phenotypic results for these samples showed inducible resistance, indicating that the T allele was present and only real-time PCR was sensitive enough to detect it compared to sequencing. Hence, real-time PCR was superior to sequencing as it requires smaller DNA concentration and may detect both mutation profiles in a single test. Real-time PCR also has an advantage over the sequencing method done in our laboratory as it provides rapid test turnaround times, is less labour intensive with satisfactory test accuracy. The resulting output is a simple negative or positive for a real-time reaction i.e., looking for amplification vs interpreting sequencing chromatograms and hence less data screening. To summarize, even though 3 results were presumed discrepant between phenotypic and real-time PCR (97.6%; 123/126); 1 was found to be mixed by $hsp65$ sequencing and 2 samples detected both T28 and C28 $erm(41)$ alleles by real-time PCR. This meant that in the presumed discrepant isolates, 100% concordance between
sequencing and real-time was seen due to the real-time results. Hence, real-time PCR demonstrated slight advantage over traditional sequencing assay.

**Conclusion**

In conclusion, a real-time detection assay shortened turnaround times compared to phenotypic susceptibility testing and traditional sequencing. Probes for detecting A2058G and A2059G mutations on *rrl* were not appropriately evaluated in our study since incidence of *rrl* mutations were low. However, *rrl* was implemented in our assay for future testing to detect possible mutations that may be responsible for constitutive resistance. Multiplexing this assay could also result in conservation of reagents and hence decreased cost while running more samples on one plate/run. Whether by use of sequencing or by real-time PCR assay, there is advantage in detecting *erm*(41) variants to predict sensitivity of *M. abscessus* isolates to clarithromycin, hence impacting treatment outcomes.

**List Of Abbreviations**

**PCR**: Polymerase chain reaction  
**rRNA**: ribosomal ribonucleic acid  
**DNA**: deoxyribonucleic acid  
**LNA**: locked nucleic acids  
**CT**: Threshold cycle  
**ΔRn**: Normalized reporter value minus baseline  
**MIC**: minimum inhibitory concentration  
**CLSI**: Clinical Laboratory Standard Institute

**Declarations**

**Ethics approval and consent to participate**: Not applicable  
**Consent for publication**: Not applicable  
**Availability of data and materials**: The nucleotide datasets generated and/or analyzed during the current study are available in the NCBI under BankIt submission number 2402752 and accession numbers MW275120 - MW275245.  
**Competing interests**: None  
**Funding**: Not applicable
Author's contributions: MS developed the concept of the work, sought human resources, funding and approval for the work, analyzed, interpreted results, wrote the manuscript and obtained coauthor consent. YL performed the assay, analyses, interpreted results, wrote and edited the manuscript. DJ performed the assay and data acquisition. HS performed data analysis and interpretation. All authors read and approved the final manuscript.

Acknowledgements: The authors would like to thank all staff of National Reference Centre for Mycobacteriology, Winnipeg.

References

1. Gupta RS, Lo B, Son J (2018) Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front Microbiol 9:67. doi:10.3389/fmicb.2018.00067

2. Leão SC, Viana-Niero C, Matsumoto CK, Lima KV, Lopes ML, Palaci M, Hadad DJ, Vinhas S, Duarte RS, Lourenço MC et al (2010) Epidemic of surgical-site infections by a single clone of rapidly growing mycobacteria in Brazil. Future Microbiol 5(6):971-980. doi:10.2217/fmb.10.49

3. Brown BA, Wallace RJ Jr, Onyi GO, Dr Rosas V, Wallace RJ 3rd (1992) Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 36(1):180-184. doi:10.1128/aac.36.1.180.

4. Andrews ER, Marchand-Austin A, Ma J, Cronin K, Sharma MK, Brode SK, Marras TK, Jamieson FB (2020) Underutilization of nontuberculous mycobacterial drug susceptibility testing in Ontario, Canada, 2010–2015. Official Journal of the Association of Medical Microbiology

5. Novosad SA, Beekmann SE, Polgreen PM, Mackey K, Winthrop KL (2016) Treatment of Mycobacterium abscessus Infection. Emerg Infect Dis 22(3):511-514. doi:10.3201/eid2203.150828

6. Maurer FP, Castelberg C, Quiblier C, Böttger EC, Somoskövi A (2014) Erm(41)-dependent Inducible Resistance to Azithromycin and Clarithromycin in Clinical Isolates of Mycobacterium abscessus. J Antimicrob Chemother 69(6):1559-1563. doi:10.1093/jac/dku007

7. Nash KA, Brown-Elliot BA, Wallace RJ Jr (2009) A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53(4):1367-1376. doi:10.1128/AAC.01275-08

8. Sander P, Prammananan T, Meier A, Frischkorn K, Böttger EC (1997) The role of ribosomal RNAs in macrolide resistance. Mol Microbiol 26(3):469-480. doi:10.1046/j.1365-2958.1997.5811946.x

9. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Böttger EC (1996) Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 40(7):1676-1681

10. Vester B, Douthwaite S (2001) Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrob Agents Chemother 45(1):1-12. doi:10.1128/AAC.45.1.1-12.2001

11. Ringuet H, Akoua-Koffi C, Honore S, Varnerot A, Vincent V, Berche P, Gaillard JL, Pierre-Audigier C (1999) hsp65 sequencing for identification of rapidly growing mycobacteria. J Clin Microbiol 37(3):852–857. doi:10.1128/JCM.37.3.852-857.1999
12. Shallom SJ, Moura NS, Olivier KN, Sampaio EP, Holland SM, Zelazny AM (2015) New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the *Mycobacterium abscessus* Group. J Clin Microbiol 53(11):3430-3437. doi:10.1128/JCM.01714-15

13. Brown-Elliot BA, Vasilreddy S, Vasilreddy R, Iakhlaeva E, Howard ST, Nash K, Parodi N, Strong A, Gee M, Smith T, et al (2015) Utility of Sequencing the *erm*(41) Gene in Isolates of *Mycobacterium abscessus* subsp. *abscessus* with Low and intermediate Clarithromycin MICs. J Clin Microbiol 53(4):1211-1215. doi:10.1128/JCM.02950-14

14. Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P (2015) Inducible and Acquired Clarithromycin Resistance in the *Mycobacterium abscessus* Complex. PLoS One 10(10):e0140166. doi:10.1371/journal.pone.0140166

15. Maurer FP, Rüegger V, Ritter C, Bloemberg GV, Böttger EC (2012) Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of *Mycobacterium abscessus* in the presence of inducible *erm*(41). J Antimicrob Chemother 67(11):2606-2611. doi:10.1093/jac/dks279

16. Leung KL, Yip CW, Cheung WF, Lo AC, Ko WM, Kam KM (2009) Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory. J Appl Microbiol 107(5):1433-1439. doi:10.1111/j.1365-2672.2009.04324.x

17. Zhu YC, Mitchell KK, Nazarian EJ, Escuyer VE, Musser KA (2015) Rapid prediction of inducible clarithromycin resistance in *Mycobacterium abscessus*. Mol Cell Probes 29(6):514-516. doi:10.1016/j.mcp.2015.08.007

18. Nakanaga K, Sekizuka T, Fukano H, Sakakibara Y, Takeuchi F, Wada S, Ishii N, Makino M, Kuroda M, Hoshino Y (2014) Discrimination of *Mycobacterium abscessus* subsp. *massiliense* from *Mycobacterium subsp. abscessus* in Clinical Isolates by Multiplex PCR. J Clin Microbiol 52(1):251-259. doi:10.1128/JCM.01327-13

19. Christianson S, Grierson W, Kein D, Tyler AD, Wolfe J, Sharma MK (2016) Time-to-Detection of Inducible Macrolide Resistance in *Mycobacterium abscessus* Subspecies and Its Association with the Erm(41) Sequenvar. PLoS One 11(8):e0158723. doi:10.1371/journal.pone.0158723

20. Kim H, Kim BJ, Kook Y, Yun Y, Shin JH, Kim B, Kook YH (2010) *Mycobacterium massiliense* is differentiated from *Mycobacterium abscessus* and *Mycobacterium bolletii* by erythromycin ribosome methyltransferase gene (*erm*) and clarithromycin susceptibility patterns. Microbiol Immunol 54(6):347-353. doi:10.1111/j.1348-0421.2010.00221.x

21. Shallom SJ, Gardina PJ, Myers TG, Sebastian Y, Conville P, Calhoun LB, Tettelin H, Olivier KN, Uzel G, Sampaio EP (2013) New Rapid Scheme for Distinguishing the Subspecies of the *Mycobacterium abscessus* Group and Identifying *Mycobacterium massiliense* Isolates with Inducible Clarithromycin Resistance. J Clin Microbiol 51(9):2943-2949. doi:10.1128/JCM.01132-13

22. Vianna JS, Machado D, Ramis IB, Silva FP, Bierhals DV, Abril MA, von Groll A, Ramos DF, Lourenço MCS, Viveiros M, da Silva PEA (2019) The Contribution of Efflux Pumps in *Mycobacterium abscessus* Complex Resistance to Clarithromycin. *Antibiotics (Basel)* 8(3):153. doi:10.3390/antibiotics8030153

23. Lipworth S, Hough N, Leach L, Morgan M, Jeffery K, Andersson M, Robinson E, Smith EG, Crook D, Peto T et al (2018) Whole-Genome Sequencing for Predicting Clarithromycin Resistance in *Mycobacterium abscessus*. Antimicrob Agents Chemother 63(1):1204-1218. doi:10.1128/AAC.01204-18
### Tables

#### Table 1

Primers used for sequencing of *hsp65*, *erm(41)* and *rrl* of the *M. abscessus*

| Primer | Target Gene | Sequence                     | Annealing Temp (°C) | Reference |
|--------|-------------|------------------------------|---------------------|-----------|
| TB11   | *hsp65*     | 5’-ACCAACGATGGTGTGTCCAT-3’  | 60                  | 11        |
| TB12   | *hsp65*     | 5’-CTTGTCGAAGGCCATACCCT-3’  | 60                  | 11        |
| ermF   | *erm(41)*   | 5’-GACCGGGGCCTTCTTCGTGAT-3’ | 60                  | 12        |
| ermR1  | *erm(41)*   | 5’-GACTTCCCCGCACCGATTCC-3’  | 60                  | 12        |
| erm41-2| *erm(41)*   | 5’-GGATTCCGGCGTCAAGAGACTC-3’| 60                  | 9         |
| erm41-3| *erm(41)*   | 5’-CGAGCCCCGCCCTACCAAGTCAC-3’| 60                  | 7         |
| erm41-4| *erm(41)*   | 5’-CCGGCCCGTAGCGTCCAATG-3’  | 60                  | 13        |
| erm41-5| *erm(41)*   | 5’-ACTCCCCCTGAGCGA ACAC-3’  | 60                  | 7         |
| 19F    | *rrl*       | 5’-GTAGCGAAATTCCCTTGCGG-3’  | 55                  | 14        |
| 21R    | *rrl*       | 5’-TTCCCCGGCTTAGATGCTTCAG-3’| 55                  | 14        |
| SP1    | *rrl*       | 5’-CCTGCACGAAATGGCCGTAACG-3’| 55                  | 15        |
| SP2mod | *rrl*       | 5’-CACCAGAGGTTTCGTCGCCGTC-3’| 55                  | 15        |

#### Table 2

Probes and primers used in the real-time assay for *M. abscessus*
| Target | Sequence | Reference |
|--------|----------|-----------|
| 16S    | Abc-chel 16S | 5’-6FAM-ACC ACA CAC TTC A-MGB-NFQ-3’ | 16 |
| F Primer16S | 5’-ATAAGCCTGGGAAACTGGGTCTA-3’ |
| R Primer16S | 5’-CCACACCGCAAAAAGCTTTT-3’ |
| 16F Primer | 5’-ATAAGCCTGGGAAACTGGGTCTA-3’ |
| 16R Primer | 5’-CCACACCGCAAAAAGCTTTT-3’ |
| Full length | erm(41)_probe1 | 5’-6FAM-TGC TAG CCG TCG AGC TGC ATC C-QSY-3’ | 17 |
| ermd(41) | F PrimerTR | 5’-TCAGGGGAGTTCGTTGTGGAT-3’ |
| F PrimerTR | 5’-TCTTCCTCGGCAAACCGT-3’ |
| 16erm(41) | erm(41)T28 | 5’-HEX-CCA +G+T+G GGG C-IABkFQ-3’ | 12 |
| erm(41)C28 | 5’-6FAM-CCA +G+C+G GGGC-IABkFQ-3’ |
| F PrimerE28 | 5’-GAGCATGGGCGATTCATGATG-3’ |
| R PrimerE28 | 5’-TGAGCGAACACCCTCGATG-3’ |
| 23S rrfl | 23S_A2058 | 5’-6FAM-CGGCAGGACGAAAGACC-BHQ1-3’ | 12 |
| 23S_C2058 | 5’-6FAM-CGGCAGGACGAAAGACC-BHQ1-3’ |
| F PrimerR2058 | 5’-GCGAAATTGCACTACGAGTAAAG-3’ |
| R PrimerR2058 | 5’-CCTATCCTACACAAACCAGACC-3’ |

MGB, minor groove binder; HEX, hexachlorofluorescein; 6FAM, 6-carboxyfluorescein; IABkFQ, Iowa Black fluorescent quencher; BHQ1, Black Hole quencher; NFQ, Non-fluorescent Quencher; +, LNA bases

Table 3
Clarithromycin Minimum Inhibitory Concentration (MIC) interpretations for *M. abscessus* isolates
| hsp65 Identification          | S  | IR | R  | Total |
|-------------------------------|----|----|----|-------|
| *M. abscessus subsp. abscessus* | 22*| 70 | 2  | 94*   |
| *M. abscessus subsp. bolletii* | 2  | 5  | -  | 7     |
| *M. abscessus subsp. massiliense* | 21 | 1  | 1  | 23    |
| *M. abscessus subspecies mixed* | 2  | -  | -  | 2     |
| **Total**                     | 47 | 76 | 3  | 126   |

S, Sensitive (MIC ≤ 2); IR, Inducible Resistance (MIC ≥ 8 on day 7 or later of susceptibility testing); R, Resistant (MIC ≥ 8 on day 3 of susceptibility testing); *2 mixed cultures of *M. abscessus* subsp. *abscessus*, each found to have both wild type T28 and mutation C28 in *erm*(41)

**Table 4**
Comparisons of mutations found in *erm*(41) and *rrl* for each subspecies of the *M. abscessus* using sequencing and real-time PCR.
| Subspecies            | # of Samples | Phenotypic Result | Sequencing Results | Real-time PCR Results |
|-----------------------|--------------|-------------------|--------------------|----------------------|
|                       |              | Full-length/truncated  | erm\textsubscript{41} position 28 | rrl position 2058   | Full-length/truncated  | erm\textsubscript{41} position 28 | rrl position 2058 |
| **M. abscessus subsp.** |              |                   |                    |                      |                       |                          |                     |
| abscessus             |              |                   |                    |                      |                       |                          |                     |
|                       | 67           | IR                | Full               | T                    | A                    | Full                  | T                    | A                     |
|                       | 1            | R*                | Full               | T                    | A                    | Full                  | T                    | A                     |
|                       | 1            | S*                | Full               | T                    | A                    | Full                  | T                    | A                     |
|                       | 1            | R                 | Full               | T                    | C                    | Full                  | T                    | C                     |
|                       | 21           | S                 | Full               | C                    | A                    | Full                  | C                    | A                     |
|                       | 2            | IR                | Full               | C                    | A                    | Full                  | T + C                | A                     |
|                       | 1            | IR*               | Full               | C                    | A                    | Full                  | C                    | A                     |
| **M. abscessus subsp. bolletii** |              |                   |                    |                      |                       |                          |                     |
| abscessus              |              |                   |                    |                      |                       |                          |                     |
|                       | 5            | IR                | Full               | T                    | A                    | Full                  | T                    | A                     |
|                       | 2            | S                 | Full               | C                    | A                    | Full                  | C                    | A                     |
| **M. abscessus subsp. massiliense** |              |                   |                    |                      |                       |                          |                     |
| massiliense            |              |                   |                    |                      |                       |                          |                     |
|                       | 21           | S                 | Truncated           | T                    | A                    | Truncated              | T                    | A                     |
|                       | 1            | R                 | Truncated           | T                    | C                    | Truncated              | T                    | C                     |
|                       | 1            | IR                | Full               | T                    | A                    | Full                  | T                    | A                     |
| **M. abscessus**       |              |                   |                    |                      |                       |                          |                     |
| abscessus              |              |                   |                    |                      |                       |                          |                     |
|                       | 1            | S                 | Full               | C                    | A                    | Full                  | C                    | A                     |
|                       | 1            | S                 | Truncated           | T                    | A                    | Full                  | C                    | A                     |

* Discrepant phenotypic result to what was expected with real-time results

** M. abscessus subspecies with two \textit{hsp65} gene sequences